FTC’s Stern POM Opinion Expands Disease Claim Findings

The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.